New drug Abaloparatide

We are aware that the National Institute for Health and Care Excellence (NICE) has announced the approval of Abaloparatide, a new bone-strengthening medication for post-menopausal women at high risk of fractures due to osteoporosis. It is believed this drug will be available through the NHS in England within the next three months.

At this time, we do not have detailed information regarding the side effects, contraindications, prescribing guidelines, eligibility criteria, or supply logistics for Abaloparatide. Additionally, it remains unclear whether this medication will be initiated by general practitioners or if it will require intervention by specialist secondary care.

We are committed to keeping our patients informed and will provide updates as soon as more information becomes available.